获取途径

作者

Yuxiang Ma Shaoyan Lin Qun Chen Jinhui Xue Yunpeng Yang Aimin Zang Ying Cheng Yiping Zhang Xiangcai Wang Zhendong Chen Song Qu Jianbo He Chuanben Chen Chuan Jin Dongyuan Zhu Qingshan Li Xianling Liu Wuyun Su Yi Ba Weiwei Li

作者单位

¹³Department of Medical Oncology of Respiratory, Guangxi Medical University Cancer Hospital, Cancer Institute of Guangxi, Nanning 530021, Guangxi, China ¹⁹Department of Medical Oncology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010050, China ¹Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng East Road, Guangzhou 510060, China ¹⁰Department of Oncology, First Affiliated Hospital of Gannan Medical University, Ganzhou 341001, China ¹²Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Cancer Institute of Guangxi, Nanning 530021, Guangxi, China ²These authors contributed equally ⁵Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou 350000, China ¹⁶Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China ⁷Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding 071000, China ¹¹Department of Medical Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230093, China ²¹Department of Translational Medicine, Amoy Diagnostics Co., Ltd, Xiamen 361027, China ²⁰Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China ³Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan 250000, China ¹⁷Department of Oncology, Affiliated Hospital of Chengde Medical University, Chengde 067000, China ⁴Department of Intensive Care Unit, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng East Road, Guangzhou 510060, China ⁸Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun 130012, China ¹⁵Department of Medical Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou 510095, China ⁶Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng East Road, Guangzhou 510060, China ¹⁴Department of Head and Neck Radiation Oncology, Fujian Cancer Hospital, Fuzhou 350000, China ⁹The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, Zhejiang, China ¹⁸Department of Oncology, Second Xiangya Hospital, Central South University, Changsha 410011, China

刊名

Cell Reports Medicine

年份

2025

页码

102396

ISSN

2666-3791

关键词

bifunctional PD-1 CTLA-4 antibody biomarker phase 1 trial nasopharyngeal carcinoma cervical cancer non-small cell lung cancer

摘要

QL1706 has shown promising efficacy in solid tumors in a phase 1/1b study. Here, we report updated long-term survival outcomes and biomarker analyses. Among 468 patients treated with QL1706 , median progression-free survival and overall survival are 1.5 and 14.2 months for non-small cell lung cancer , 1.9 and 20.2 months for nasopharyngeal carcinoma , and 4.2 and 18.6 months for cervical cancer , respectively. Liver metastasis is correlated with poor progression-free survival and overall surv...更多

QL1706 has shown promising efficacy in solid tumors in a phase 1/1b study. Here, we report updated long-term survival outcomes and biomarker analyses. Among 468 patients treated with QL1706 , median progression-free survival and overall survival are 1.5 and 14.2 months for non-small cell lung cancer , 1.9 and 20.2 months for nasopharyngeal carcinoma , and 4.2 and 18.6 months for cervical cancer , respectively. Liver metastasis is correlated with poor progression-free survival and overall survival in NSCLC and poor OS in CC, while elevated lactate dehydrogenase is linked to shorter PFS and OS in NPC. CDK4/11q13 diploid or the expression of GZMK & MYC distinguishes NPCs with the most favorable PFS. In NSCLC, PD-L1/TIL or a low ARG1:CXCL13 ratio indicates better outcomes. QL1706 offers long-term survival benefits in solid tumors, with identified molecular markers aiding in selecting suitable candidates. This study has been registered on clinicaltrials.gov .收起

文献类型

期刊